ArticleNanoscale advances2026
Biodegradable folate-mediated chitosan-CQD nanocarriers for targeted and stimuli-responsive cisplatin delivery in melanoma.
Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymeric nanoparticles provide an effective platform for drug delivery owing to their biocompatibility, biodegradability, and high drug-loading capacity. Chitosan, a natural cationic biopolymer, is particularly attractive because of its mucoadhesive nature, pH responsiveness, and structural stability. In this work, a cisplatin-loaded chitosan-based nanocarrier was developed by integrating green-synthesized fluorescent carbon quantum dots (CQDs) and surface functionalizing them with folic acid (FA) to enhance melanoma-targeted theranostic performance. Physicochemical characterization using UV-vis spectroscopy, dynamic light scattering, and FTIR confirmed successful nanoparticle formation, surface functionalization, and colloidal stability, with a high cisplatin encapsulation efficiency (>70%). Hemocompatibility studies revealed negligible hemolysis, indicating excellent blood compatibility. The FA-conjugated cisplatin-loaded chitosan-CQD nanoconjugates (FA-CisCCNPs) exhibited significantly enhanced cytotoxicity against B16 melanoma cells, with markedly lower IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.